

GÃ¼nter Niegisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/923486/publications.pdf>

Version: 2024-02-01

113
papers

2,647
citations

172386

29
h-index

233338

45
g-index

138
all docs

138
docs citations

138
times ranked

3916
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	6.3	153
2	Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. <i>Annals of Oncology</i> , 2011, 22, 288-294.	0.6	129
3	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	0.9	104
4	Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. <i>Clinical Epigenetics</i> , 2018, 10, 1.	1.8	93
5	Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 1.	3.5	76
6	The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. <i>Molecular Cancer</i> , 2015, 14, 108.	7.9	72
7	Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1770-1779.	0.8	68
8	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 105-120.	5.1	61
9	Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>Annals of Oncology</i> , 2018, 29, 361-369.	0.6	57
10	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	0.9	56
11	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016, 69, 634-641.	0.9	53
12	Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. <i>Targeted Oncology</i> , 2016, 11, 783-798.	1.7	52
13	Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful Surrogate. <i>Journal of Urology</i> , 2014, 191, 898-906.	0.2	51
14	Effects of novel HDAC inhibitors on urothelial carcinoma cells. <i>Clinical Epigenetics</i> , 2018, 10, 100.	1.8	51
15	Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 673-678.	0.7	50
16	HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2013, 3, 255.	1.3	49
17	Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 299-312.	1.9	48
18	A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. <i>Journal of Cancer</i> , 2018, 9, 1337-1348.	1.2	45

#	ARTICLE	IF	CITATIONS
19	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	2.6	41
20	Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. <i>PLoS ONE</i> , 2017, 12, e0176287.	1.1	39
21	Rs710521 [A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2010, 84, 967-978.	1.9	37
22	Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 742-757.	1.5	36
23	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	0.9	36
24	The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors. <i>Bladder Cancer</i> , 2016, 2, 449-463.	0.2	34
25	Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. <i>Clinical Epigenetics</i> , 2014, 6, 29.	1.8	33
26	Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 966-974.	0.8	33
27	Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 160.e1-160.e13.	0.8	33
28	Rs11892031 [A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2012, 86, 1369-1378.	1.9	32
29	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014, 113, E137-43.	1.3	31
30	Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20500-20517.	1.8	30
31	Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?. <i>European Urology</i> , 2013, 64, 355-357.	0.9	29
32	Canonical Notch signalling is inactive in urothelial carcinoma. <i>BMC Cancer</i> , 2014, 14, 628.	1.1	29
33	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 590.	1.8	29
34	Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 59.	3.5	27
35	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	0.9	27
36	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 144.	3.5	27

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
38	Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). <i>Oncology</i> , 2015, 89, 70-78.	0.9	26
39	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26
40	Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99). <i>European Urology</i> , 2011, 60, 1087-1096.	0.9	25
41	MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 670-677.	0.8	24
42	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	1.1	24
43	Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. <i>Cancers</i> , 2020, 12, 337.	1.7	23
44	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncol</i> , 2018, 57, 491-497.	0.8	22
45	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
46	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
47	CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, e002949.		22
48	HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment. <i>Current Medicinal Chemistry</i> , 2017, 24, 4151-4165.	1.2	21
49	Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 495-500.	0.9	20
50	Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. <i>Non-coding RNA</i> , 2015, 1, 266-284.	1.3	20
51	Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 544.e11-544.e23.	0.8	17
52	Epigenetics of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2015, 1238, 183-215.	0.4	16
53	Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. <i>Oncotarget</i> , 2016, 7, 41320-41335.	0.8	16
54	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	0.9	15

#	ARTICLE	IF	CITATIONS
55	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	0.9	15
56	Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells. <i>Frontiers in Immunology</i> , 2021, 12, 782448.	2.2	15
57	Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. <i>Archives of Toxicology</i> , 2012, 86, 195-203.	1.9	14
58	HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2135.	1.8	14
59	Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane. <i>Biochemical Journal</i> , 2006, 395, 117-123.	1.7	13
60	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1680.	1.8	13
61	Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. <i>Genes</i> , 2021, 12, 260.	1.0	13
62	Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment. <i>Molecules</i> , 2021, 26, 1294.	1.7	13
63	Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 395-398.	0.9	12
64	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	0.9	12
65	Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 405-413.	0.2	12
66	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. <i>Cancer Medicine</i> , 2017, 6, 186-194.	1.3	12
67	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e483-e490.	0.9	12
68	Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. <i>Scientific Reports</i> , 2020, 10, 3808.	1.6	12
69	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	2.6	11
70	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	1.6	11
71	Tumor immunotherapyâ€“the potential of epigenetic drugs to overcome resistance. <i>Translational Cancer Research</i> , 2018, 7, 1151-1160.	0.4	11
72	Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 71-79.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e15-256.e21.	0.8	10
74	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
75	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	0.7	10
76	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. <i>European Journal of Cancer</i> , 2021, 155, 64-72.	1.3	10
77	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 413-413.	0.8	10
78	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 7-14.e3.	0.9	9
79	Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9433.	1.8	9
80	Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. <i>Urologia Internationalis</i> , 2018, 101, 224-231.	0.6	8
81	Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. <i>Scientific Reports</i> , 2019, 9, 14476.	1.6	8
82	Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. <i>Current Opinion in Urology</i> , 2011, 21, 434-439.	0.9	7
83	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018, 4, 937-945.	1.6	7
84	Nomograms including the UBC [®] Rapid test to detect primary bladder cancer based on a multicentre dataset. <i>BJU International</i> , 2022, 130, 754-763.	1.3	6
85	Influence of a Deep Learning Noise Reduction on the CT Values, Image Noise and Characterization of Kidney and Ureter Stones. <i>Diagnostics</i> , 2022, 12, 1627.	1.3	6
86	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019, 37, 2081-2090.	1.2	5
87	Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. <i>Cancers</i> , 2020, 12, 1023.	1.7	5
88	Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?. <i>Bladder Cancer</i> , 2015, 1, 97-103.	0.2	4
89	Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 1376.	1.7	4
90	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 323-323.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression. <i>Scientific Data</i> , 2022, 9, .	2.4	4
92	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	0.9	3
93	Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?. <i>British Journal of Cancer</i> , 2020, 122, 453-454.	2.9	3
94	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 426-426.	0.8	3
95	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4552-4552.	0.8	3
96	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	0.9	2
97	Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?. <i>Translational Andrology and Urology</i> , 2018, 7, S744-S746.	0.6	2
98	Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722210876.	0.9	2
99	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 494-498.	0.9	1
100	Epigenetic Treatment Options in Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 289-317.	0.4	1
101	PD24-03 ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
102	Targeting mTOR in urothelial cancer – Beating a dead horse or ready for prime time?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 600-601.	0.8	0
103	Real-world survival outcomes in patients with advanced urothelial cancer in Germany. <i>Annals of Oncology</i> , 2017, 28, v396-v397.	0.6	0
104	Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?. <i>Translational Andrology and Urology</i> , 2019, 8, S283-S286.	0.6	0
105	Metastatic Bladder Cancer Disease and Its Treatment. , 2019, , 403-411.		0
106	Are bladder cancer patients set at risk by minimally invasive approaches to radical cystectomy?. <i>Translational Cancer Research</i> , 2017, 6, S221-S225.	0.4	0
107	Metastatic Bladder Cancer Disease and Its Treatment. , 2018, , 1-9.		0
108	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 448-448.	0.8	0

#	ARTICLE	IF	CITATIONS
109	MP52-08 ONCOLOGICAL OUTCOMES, SURGICAL SAFETY AND COMPLICATIONS OF PATIENTS TREATED WITH SPOT SPECIFIC SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
110	Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4535-4535.	0.8	0
111	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 476-476.	0.8	0
112	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4535-4535.	0.8	0
113	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16017-e16017.	0.8	0